Yeo C P, Khoo D H, Eng P H, Tan H K, Yo S L, Jacob E
Department of Pathology, Singapore General Hospital, Singapore, Singapore.
Clin Endocrinol (Oxf). 2001 Sep;55(3):391-8. doi: 10.1046/j.1365-2265.2001.01353.x.
The prevalence of gestational transient thyrotoxicosis (GTT) in Europeans evaluated during the 8th to 14th weeks of pregnancy is 2-3%. However, there is evidence that GTT may be more common in some Asian populations. The aims of this study were to evaluate the prevalence of thyroid hormone abnormalities in Asian women in their 8th to 14th weeks of pregnancy using highly sensitive free T4 and TSH assays and to correlate these with total and free beta-hCG levels.
One hundred and eighty-four consecutive unselected Asian (Singaporean) pregnant women seen at ante-natal clinics for the first time and who were in their 8th to 14th weeks of pregnancy were tested.
Serum free T4, free T3, TSH, total beta-hCG and free beta-HCG levels were measured on the Vitros ECi system (Johnson & Johnson Ortho-Clinical Diagnostics, Amersham, UK) which employs chemiluminescent immunochemical technology. This free T4 assay is free of biases related to serum binding capacity. The TSH assay used was a third generation assay. Thyrotrophin-receptor antibody (TRAb) levels were measured using LUMItest TRAK (BRAHMS Diagnostica, Berlin, Germany).
Two subjects (1.1%) were found to have Graves' disease. Elevated free T4, free T3, total T3 and suppressed TSH were seen in 14.8%, 3.3%, 26.4% and 33.0% of the remaining 182 pregnant women, respectively. Total and free beta-hCG correlated negatively with TSH (r = -0.30, P < 0.0001 and r = -0.29, P < 0.0001, respectively), positively with fT4 (r = 0.283, P < 0.001 and r = 0.253, P < 0.001) and fT3 (r = 0.273, P < 0.001 and r = 0.204, P < 0.01). 11.0% of cases had gestational thyrotoxicosis (GT) defined as elevated free T4 (> 19.1 pmol/l), suppressed TSH (< 0.36 mIU/l) and TRAb levels within the reference interval (0-0.9 U/l). The prevalence of GT was significantly higher in patients tested at 8-11 weeks compared to those evaluated at 12-14 weeks (14.4% vs. 4.7%, P < 0.05). Total beta-hCG (P = 0.0002), free beta-hCG (P < 0.0001) and free T4 (P = 0.02) levels were higher and TSH levels (P = 0.01) lower in patients tested at 8-11 weeks. Significant positive correlations between both total and free beta-hCG with free T4 were seen at 8-11 weeks but not in patients tested at 12 weeks or later. TT3 levels were similar in the two groups.
Using sensitive assays, the prevalence of gestational thyrotoxicosis in Asian women was found to be 11.0% and was significantly higher in subjects at 8-11 weeks of gestation than at 12-14 weeks. The positive correlation between hCG and free T4 seen in patients tested at 8-11 weeks was absent in patients tested at later stages of the first trimester. Future studies investigating the entity of gestational thyrotoxicosis, at least in Asian patients, should focus on patients at earlier stages of gestation than currently practised.
在妊娠第8至14周接受评估的欧洲人中,妊娠期一过性甲状腺毒症(GTT)的患病率为2%-3%。然而,有证据表明GTT在一些亚洲人群中可能更为常见。本研究的目的是使用高灵敏度的游离T4和促甲状腺激素(TSH)检测方法评估亚洲女性妊娠第8至14周甲状腺激素异常的患病率,并将其与总β-人绒毛膜促性腺激素(β-hCG)和游离β-hCG水平相关联。
对184例首次在产前诊所就诊、妊娠第8至14周的连续未选择的亚洲(新加坡)孕妇进行检测。
在采用化学发光免疫化学技术的Vitros ECi系统(英国阿默舍姆强生奥多临床诊断公司)上测量血清游离T4、游离T3、TSH、总β-hCG和游离β-hCG水平。这种游离T4检测不受血清结合能力相关偏差的影响。所使用的TSH检测为第三代检测方法。使用LUMItest TRAK(德国柏林BRAHMS诊断公司)测量促甲状腺激素受体抗体(TRAb)水平。
发现2例受试者(1.1%)患有格雷夫斯病。在其余182例孕妇中,分别有14.8%、3.3%、26.4%和33.0%的孕妇出现游离T4、游离T3及总T3升高和TSH降低。总β-hCG和游离β-hCG与TSH呈负相关(r分别为-0.30,P<0.0001和r=-0.29,P<0.0001),与游离T4呈正相关(r分别为0.283,P<0.001和r=0.253,P<0.001),与游离T3呈正相关(r分别为0.273,P<0.001和r=0.204,P<0.01)。11.0%的病例患有妊娠期甲状腺毒症(GT),定义为游离T4升高(>19.1 pmol/L)、TSH降低(<0.36 mIU/L)且TRAb水平在参考区间(0-0.9 U/L)内。与在妊娠12-14周接受评估的患者相比,在妊娠8-11周接受检测的患者中GT的患病率显著更高(14.4%对4.7%,P<0.05)。在妊娠8-11周接受检测的患者中,总β-hCG(P=0.0002)、游离β-hCG(P<0.0001)和游离T4(P=0.02)水平更高,TSH水平(P=0.01)更低。在妊娠8-11周接受检测的患者中,总β-hCG和游离β-hCG与游离T4之间均存在显著正相关,但在妊娠12周及以后接受检测的患者中未观察到这种相关性。两组的总T3水平相似。
使用灵敏检测方法发现,亚洲女性妊娠期甲状腺毒症的患病率为11.0%,且在妊娠8-11周的受试者中显著高于妊娠12-14周的受试者。在妊娠8-11周接受检测的患者中观察到的hCG与游离T4之间的正相关在妊娠早期后期接受检测的患者中不存在。未来关于妊娠期甲状腺毒症实体的研究,至少在亚洲患者中,应关注比目前实践中更早妊娠阶段的患者。